1. Exceptional pemetrexed sensitivity can predict therapeutic benefit from subsequent chemotherapy in metastatic non-squamous non-small cell lung cancer
   Ji Hyun Park et al, 2019, Journal of Cancer Research and Clinical Oncology CrossRef
2. Human drug efflux transporter ABCC5 confers acquired resistance to pemetrexed in breast cancer
   Jihui Chen et al, 2021, Cancer Cell International CrossRef
3. MTAP-deficiency could predict better treatment response in advanced lung adenocarcinoma patients initially treated with pemetrexed-platinum chemotherapy and bevacizumab
   Wang Jing et al, 2020, Scientific Reports CrossRef
4. Pemetrexed ameliorates Con A-induced hepatic injury by restricting M1 macrophage activation
   Zhaiyi Liu et al, 2023, International Immunopharmacology CrossRef
5. Increase in resistance to anticancer drugs involves occludin in spheroid culture model of lung adenocarcinoma A549 cells
   Hiroaki Eguchi et al, 2018, Scientific Reports CrossRef
6. Sequential administration of pemetrexed and cisplatin reprograms tumor immune microenvironment and potentiates PD-1/PD-L1 treatment in a lung cancer model
   Jinxiang Yu et al, 2022, Journal of Investigative Medicine CrossRef
7. ZNF139 increases multidrug resistance in gastric cancer cells by inhibiting miR-185
   Bibo Tan et al, 2018, Bioscience Reports CrossRef
8. High BLM Expression Predicts Poor Clinical Outcome and Contributes to Malignant Progression in Human Cholangiocarcinoma
   Xiaolong Du et al, 2021, Frontiers in Oncology CrossRef